Is Veracyte, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Veracyte, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 56, a Price to Book Value of 1.80, and a PEG Ratio of 0.12, suggesting strong growth potential relative to its price. In comparison, peers such as TransMedics Group, Inc. have a P/E of 50.23 and an EV to EBITDA of 37.01, while iRhythm Technologies, Inc. shows a risky valuation with a P/E of -111.60.
Despite a challenging year-to-date return of -7.25% compared to the S&P 500's 15.47%, Veracyte has demonstrated strong performance over three years with a return of 128.70%, outpacing the benchmark's 78.85%. This performance, alongside its attractive valuation metrics, reinforces the view that Veracyte is currently undervalued.